Support info of Continuous intravenous pumping (CIP) of recombinant human endostatin (Endostar) combined with concurrent radiochemotherapy in patients with unresectable stage Ⅲ non-small-cell lung cancer:preliminary data of a prospective multicenter phaseⅡclinical trial

中华放射肿瘤学杂志


	2016, Vol. 25(2): 114-118 DOI: 10.3760/cma.j.issn.1004-4221.2016.02.006

	Continuous intravenous pumping (CIP) of recombinant human endostatin (Endostar) combined with concurrent radiochemotherapy in patients with unresectable stage Ⅲ non-small-cell lung cancer:preliminary data of a prospective multicenter phaseⅡclinical trial
	Ma Honglian,Hui Zhouguang,Zhao Lujun,Xu Yujin,Zhai Yirui,Eu Runye,Pang Qingsong,Zhu Guangying,Li Dongming,Tang Yu,Liang Jun,Kong yue,Chen Ming,Wang Lyuhua
	Department of Radiation Oncology,Zhejiang Cancer Hospital,Key Laboratory of Radiation Oncology in Zhejiang Province,Hangzhou 310022,China (Ma HL,Xu YJ,Kong Y,Chen M);Department of Radiation Oncology,Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,Beijing 10021,China (Hui ZHG,Zhai YR,Wu RY,Tang Y,Liang J,Wang LH);Department of Radiation Oncology,Tianjin Medical University Cancer Hospital,Tianjin 300060,China (Zhao LJ,Pang QS);Department of Radiation Oncology,Peking University School of Oncology,Beijing Cancer Hospital,Beijing 100142,China (Li DM,Zhu GY)
	Received 2015-04-21 Revised null
	Supporting info


	null